Biomatics Capital Partners
Biomatics Capital Partners is a Seattle-based healthcare and life sciences venture firm.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Biomatics Capital Partners Information
Geographic Data
Address: 719 2nd Ave Ste 1402
City: Seattle
State: WA
Zip: 98104
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$500M
Social
Linkedin
Crunchbase
Metrics
5,333,267Website Global Rank
1,725Website Monthly Traffic
Twitter Followers
Description
Biomatics Capital Partners is a Seattle-based healthcare and life sciences venture firm. Biomatics is a $200 million fund that focuses on early-stage investments, primarily in genomics and digital health. Co-founders and General Partners Dr. Boris Nikolic and Julie Sunderland have invested together in emerging technology, health care, and life science ventures since 2010, leveraging their deep technical knowledge and partnering expertise with an established network of leading academics, pharma executives and venture capital firms.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2016 | AiCure | Series A | 12.3M |
| 7/2018 | Omniome | Series B | 0 |
| 8/2016 | BlueTalon | Series A | 0 |
| 11/2019 | EGenesis | Series B | 0 |
| 3/2017 | Aledade | Series B | 40.2M |
| 3/2017 | EGenesis | Series A | 0 |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 6/2017 | Twist Bioscience | Venture Round | 27M |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 12/2017 | Aledade | Series C | 46.1M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 1/2016 | Grail | Series A | 100M |
| 1/2017 | BlackThorn Therapeutics | Series A | 14M |
| 1/2020 | Omniome | Series C | 60M |
| 7/2018 | Verana Health | Series C | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 11/2017 | AiCure | Series B | 15M |
| 2/2015 | Verana Health | Series B | 0 |
| 7/2018 | Qihan Biotech | Series A | 7.8M |
| 5/2019 | Thrive Earlier Detection | Series A | 110M |
| 11/2019 | AiCure | Series C | 24.5M |
| 5/2015 | Denali Therapeutics | Series A | 217M |
| 1/2021 | Encodia | Series C | 75M |
| 5/2019 | Verve Therapeutics | Series A | 58.5M |
| 6/2018 | Cytrellis Biosystems | Series B | 0 |
| 6/2020 | Verve Therapeutics | Series A | 63M |
| 1/2021 | Encodia | Series C | 0 |
| 1/2021 | Verve Therapeutics | Series B | 0 |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 6/2020 | Verve Therapeutics | Series A | 0 |
| 1/2020 | Omniome | Series C | 0 |
| 11/2019 | EGenesis | Series B | 0 |
| 11/2019 | AiCure | Series C | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 0 |
| 5/2019 | Thrive Earlier Detection | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
